Bt354

Overview

Bt354 is an orally active STAT3 inhibitor with IC 50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis , and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer , prostate cancer and neuropathic pain.

Application

Products | Products > Disease Areas > Pain | Products > Disease Areas > Glioblastoma | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Glioma | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy

Product Information

• Catalog No.: HY-155949
• CAS No.: 931305-29-2
• Molecular Formula: C21H21N3O3S
• Molecular Weight: 395.48
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source